Unknown

Dataset Information

0

Kernelized rank learning for personalized drug recommendation.


ABSTRACT: Motivation:Large-scale screenings of cancer cell lines with detailed molecular profiles against libraries of pharmacological compounds are currently being performed in order to gain a better understanding of the genetic component of drug response and to enhance our ability to recommend therapies given a patient's molecular profile. These comprehensive screens differ from the clinical setting in which (i) medical records only contain the response of a patient to very few drugs, (ii) drugs are recommended by doctors based on their expert judgment and (iii) selecting the most promising therapy is often more important than accurately predicting the sensitivity to all potential drugs. Current regression models for drug sensitivity prediction fail to account for these three properties. Results:We present a machine learning approach, named Kernelized Rank Learning (KRL), that ranks drugs based on their predicted effect per cell line (patient), circumventing the difficult problem of precisely predicting the sensitivity to the given drug. Our approach outperforms several state-of-the-art predictors in drug recommendation, particularly if the training dataset is sparse, and generalizes to patient data. Our work phrases personalized drug recommendation as a new type of machine learning problem with translational potential to the clinic. Availability and implementation:The Python implementation of KRL and scripts for running our experiments are available at https://github.com/BorgwardtLab/Kernelized-Rank-Learning. Supplementary information:Supplementary data are available at Bioinformatics online.

SUBMITTER: He X 

PROVIDER: S-EPMC6084606 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kernelized rank learning for personalized drug recommendation.

He Xiao X   Folkman Lukas L   Borgwardt Karsten K  

Bioinformatics (Oxford, England) 20180801 16


<h4>Motivation</h4>Large-scale screenings of cancer cell lines with detailed molecular profiles against libraries of pharmacological compounds are currently being performed in order to gain a better understanding of the genetic component of drug response and to enhance our ability to recommend therapies given a patient's molecular profile. These comprehensive screens differ from the clinical setting in which (i) medical records only contain the response of a patient to very few drugs, (ii) drugs  ...[more]

Similar Datasets

| S-EPMC4147917 | biostudies-literature
| S-EPMC8791487 | biostudies-literature
| S-EPMC5689632 | biostudies-literature
| S-EPMC4908328 | biostudies-literature
| S-EPMC7262997 | biostudies-literature
| S-EPMC3623628 | biostudies-literature
| S-EPMC10834597 | biostudies-literature
| S-EPMC4243090 | biostudies-literature
| S-EPMC7519645 | biostudies-literature
| S-EPMC7274464 | biostudies-literature